To determine the therapeutic effect of fingolimod on hypertrophic scars.

Forty New zealand rabbits were used to construct hypertrophic scar models on the ears, and two masses of hypertrophic scars on each ear. The rabbits were divided into 5 groups by handling method: negative control group, solvent control group, fingolimod 2.5 mg/mL group, fingolimod 5.0 mg/mL group, fingolimod 10.0 mg/mL group, each group had 8 rabbits and 32 scare wound. The thickness and mass of hypertrophic scars were measured respectively, on the 5th day after injecting drug, the hypertrophic scars were harvested and detected by histological staining.The scar cuticle thickness, scar collagen deposition and protein expression of transforming growth factor beta and connective tissue growth factor were compared.

The mass of hypertrophic scars in group fingolimod decreased significantly, the thickness of fingolimod 2.5 mg/mL group was (120.250±6.042) μm, collage deposition depressed. Compared to fingolimod 5.0 mg/mL, 10.0 mg/mL group, the expression of transforming growth factor-β and connective tissue growth factor of fingolimod 2.5 mg/mL group descended, the difference was statistically significant (P<0.05).

Fingolimod can inhibit the hypertrophic scars, and 2.5 mg/mL fingolimod has the most significant effect.